Stock Rating Upgrade
The Value Trend Rating for ADMA Biologics Inc (NASDAQ: ADMA) improved during the last several trading days from C to B reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
On 3/7/25, ADMA Biologics Inc (NASDAQ: ADMA) stock rose modestly by 0.7%, closing at $17.02. Moreover, this advance was accompanied by above average trading volume at 139% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 10.2% during the last week.
Current PriceTarget Research Rating
ADMA Biologics has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. ADMA Biologics has a slightly positive Appreciation Score of 63 and a good Power Rating of 81, triggering the Positive Value Trend Rating.
Be the first to comment